Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OPT Opthea	$3.41	$3.41	$1.79 ▼ $6.30	$524.83M	1.17	N/A	N/A
ORKA Oruka Therapeutics	$14.33 -1.6%	$13.43	$5.49 ▼ $52.32	$536.66M	-0.35	248,597 shs	120,689 shs
RAPP Rapport Therapeutics	$14.39 +1.0%	$13.58	$6.43 ▼ $29.74	$525.02M	0.62	187,339 shs	77,402 shs
TARA Protara Therapeutics	$3.04 -0.3%	$3.10	$1.60 ▼ $10.48	$117.29M	1.42	329,809 shs	214,058 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OPT Opthea	0.00%	0.00%	0.00%	0.00%	+24.45%
ORKA Oruka Therapeutics	-4.52%	+4.37%	+0.14%	+37.62%	+1,455,999,900.00%
RAPP Rapport Therapeutics	-2.40%	-8.37%	-3.00%	+41.83%	-32.54%
TARA Protara Therapeutics	-5.28%	-0.65%	-0.97%	-6.15%	+43.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
OPT Opthea	0.3657 of 5 stars	1.1	0.0	2.1	0.8	0.6
ORKA Oruka Therapeutics	2.5118 of 5 stars	3.6	0.0	1.6	2.5	0.6
RAPP Rapport Therapeutics	1.5396 of 5 stars	3.5	0.0	1.1	1.7	0.6
TARA Protara Therapeutics	2.0822 of 5 stars	3.6	1.0	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OPT Opthea	2.17	Hold	$1.33	-60.90% Downside
ORKA Oruka Therapeutics	3.20	Buy	$40.38	181.75% Upside
RAPP Rapport Therapeutics	3.00	Buy	$29.50	105.07% Upside
TARA Protara Therapeutics	3.17	Buy	$19.60	544.74% Upside

Current Analyst Ratings Breakdown

Latest TARA, RAPP, OPT, and ORKA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
8/12/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
8/6/2025	RAPP Rapport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$31.00
7/23/2025	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
7/21/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
7/8/2025	RAPP Rapport Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00
5/22/2025	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/22/2025	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$44.00
5/22/2025	TARA Protara Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$21.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OPT Opthea	$120K	4,373.61	N/A	N/A	($0.56) per share	-6.09
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$9.10 per share	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	$7.22 per share	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$3.74 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OPT Opthea	-$220.24M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/29/2025 (Estimated)
ORKA Oruka Therapeutics	-$83.72M	-$2.81	N/A	N/A	N/A	N/A	-26.26%	-24.16%	N/A
RAPP Rapport Therapeutics	-$78.31M	-$2.50	N/A	N/A	N/A	N/A	-29.99%	-28.64%	11/6/2025 (Estimated)
TARA Protara Therapeutics	-$44.60M	-$1.62	N/A	N/A	N/A	N/A	-36.87%	-33.85%	N/A

Latest TARA, RAPP, OPT, and ORKA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2025	ORKA Oruka Therapeutics	-$0.48	-$0.46	+$0.02	-$0.46	N/A	N/A
8/11/2025	Q2 2025	TARA Protara Therapeutics	-$0.43	-$0.35	+$0.08	-$0.35	N/A	N/A
8/7/2025	Q2 2025	RAPP Rapport Therapeutics	-$0.87	-$0.75	+$0.12	-$0.75	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
OPT Opthea	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OPT Opthea	N/A	1.57	N/A
ORKA Oruka Therapeutics	N/A	27.42	27.42
RAPP Rapport Therapeutics	N/A	22.75	22.75
TARA Protara Therapeutics	N/A	12.81	12.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
OPT Opthea	55.95%
ORKA Oruka Therapeutics	56.44%
RAPP Rapport Therapeutics	N/A
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
OPT Opthea	3.20%
ORKA Oruka Therapeutics	24.69%
RAPP Rapport Therapeutics	13.57%
TARA Protara Therapeutics	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
OPT Opthea	8	153.91 million	148.99 million	Not Optionable
ORKA Oruka Therapeutics	N/A	37.45 million	28.20 million	N/A
RAPP Rapport Therapeutics	N/A	36.50 million	31.55 million	N/A
TARA Protara Therapeutics	30	38.58 million	33.76 million	Optionable

TARA, RAPP, OPT, and ORKA Headlines

Recent News About These Companies

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Recommendation of "Buy" from Brokerages

August 20 at 2:37 AM | marketbeat.com

HC Wainwright Has Optimistic Outlook of TARA Q3 Earnings

August 16, 2025 | marketbeat.com

Q3 EPS Estimate for Protara Therapeutics Lifted by Analyst

August 16, 2025 | americanbankingnews.com

We're Not Very Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Rate

August 13, 2025 | finance.yahoo.com

Protara Therapeutics (NASDAQ:TARA) Announces Quarterly Earnings Results

August 12, 2025 | marketbeat.com

Protara Therapeutics Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

Protara Beats Q2 Loss Estimates

August 11, 2025 | aol.comA

Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

August 11, 2025 | globenewswire.com

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | gurufocus.com

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | globenewswire.com

Protara Therapeutics (TARA) to Release Quarterly Earnings on Tuesday

July 30, 2025 | marketbeat.com

Protara Therapeutics (NASDAQ:TARA) Shares Up 11% - Still a Buy?

July 22, 2025 | marketbeat.com

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - The Manila Times

July 2, 2025 | manilatimes.netM

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 2, 2025 | morningstar.comM

Protara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community - Nasdaq

July 2, 2025 | nasdaq.com

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

Protara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community

June 30, 2025 | quiverquant.comQ

Protara Therapeutics Announces Addition to the Russell 3000® Index

June 30, 2025 | globenewswire.com

Protara Therapeutics, Inc. (TARA) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

RAPT Therapeutics Appoints Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. to Board of Directors

June 23, 2025 | quiverquant.comQ

Protara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025

June 14, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TARA, RAPP, OPT, and ORKA Company Descriptions

Opthea NASDAQ:OPT

$3.41 0.00 (0.00%)

As of 08/19/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Oruka Therapeutics NASDAQ:ORKA

$14.33 -0.23 (-1.58%)

Closing price 03:59 PM Eastern

Extended Trading

$14.37 +0.04 (+0.28%)

As of 04:04 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Rapport Therapeutics NASDAQ:RAPP

$14.38 +0.15 (+1.02%)

Closing price 03:59 PM Eastern

Extended Trading

$14.32 -0.07 (-0.49%)

As of 04:10 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Protara Therapeutics NASDAQ:TARA

$3.04 -0.01 (-0.33%)

Closing price 03:59 PM Eastern

Extended Trading

$3.02 -0.02 (-0.49%)

As of 04:10 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time